AUTOIMMUNE BIOMARKERS COLLABORATIVE NETWORK

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall objective of this part of the ABCoN study is to integrate a variety of cutting edge discovery technologies in order to discover novel biomarkers that will be clinically useful in rheumatoid arthritis (RA). The ABCoN study will attempt to enroll each participant in the CLEAR registry. The specific aims are: Specific Aim 1: To determine whether specific patterns of gene expression, cell surface phenotypes, and/or levels of plasma proteins are predictive of clinical and radiographic outcome at three years disease duration in RA. This question will be studied in the CLEAR cohort. Two distinct patient groups will be compared, based on outcome: 1) patients with no evidence of erosive disease at 3 years disease duration, and 2) patients with severe erosive disease at three years disease duration. Specific Aim 2: To apply the knowledge gained in specific Aim 1 to determine whether specific patterns of gene expression, cell surface phenotypes, and/or levels of plasma proteins are predictive of clinical and X-ray outcome at three years, in the setting of recent onset rheumatoid arthritis. This question will be studied in a cohort of 600 African-American patients with early onset rheumatoid arthritis. As in specific Aim 1, two distinct patient groups will be compared, based on outcome: A) patients with no evidence of erosive disease at 3 years and B) patients with severe erosive disease at 3 years.